Login to Your Account



Delivery Still Key

Arrowhead, Others Keep the RNAi Faith Despite Doubters

By Brian Orelli
BioWorld Insight Contributing Writer

Monday, December 5, 2011

It's been a tough few years for RNAi. Last fall, Roche AG discontinued its preclinical RNAi work, and Novartis AG declined to expand an RNAi partnership with Alnylam Pharmaceuticals Inc. Pfizer Inc. followed suit earlier this year, closing its oligonucleotide therapeutics unit.

To continue reading subscribe now to BioWorld Insight

Learn More about BioWorld Insight

Already a subscriber? Sign In or Buy now to activate your subscription